MEI Pharma Files 8-K on Shareholder Vote Matters

TL;DR

MEI Pharma held a shareholder vote on Jan 30th. Details filed today.

AI Summary

MEI Pharma, Inc. filed an 8-K on January 31, 2025, reporting on matters submitted to a vote of security holders as of January 30, 2025. The filing details the company's corporate structure, including its state of incorporation (Delaware) and principal executive offices in San Diego, California.

Why It Matters

This filing indicates that MEI Pharma held a vote of its security holders, which could pertain to significant corporate decisions or changes that impact shareholders.

Risk Assessment

Risk Level: low — This is a routine filing reporting on a shareholder vote, not indicating immediate financial distress or significant operational changes.

Key Numbers

• 001-41827 — Commission File Number (Identifies the company's filing with the SEC)
• 51-0407811 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• MEI Pharma, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of Incorporation
• San Diego, California (location) — Principal Executive Offices
• January 30, 2025 (date) — Date of earliest event reported
• January 31, 2025 (date) — Date of Report

FAQ

Key Financial Figures

• $0.00000002 — nge on which registered Common Stock, $0.00000002 par value MEIP The Nasdaq Stock Mar

Filing Documents

• meip-20250130.htm (8-K) — 58KB
• 0000950170-25-011790.txt ( ) — 169KB
• meip-20250130.xsd (EX-101.SCH) — 24KB
• meip-20250130_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On January 30, 2025, MEI Pharma, Inc. (the Company") held its annual meeting of stockholders (the "Annual Meeting"). There were represented at the Annual Meeting, by proxy, 4,299,938 shares of the Company's common stock, par value $0.00000002 per share ("Common Stock"), out of a total number of 6,662,857 shares of Common Stock outstanding and entitled to vote at the Annual Meeting. The Company's stockholders voted on the following three proposals at the Annual Meeting, casting their votes as described below. Proposal 1. – Election of Director. The following individuals, who were named as nominees in the Company's definitive proxy statement relating to the Annual Meeting, were elected by the Company's stockholders by a plurality of votes cast to serve a three-year term on the Company's Board of Directors which will expire at the Company's annual meeting of stockholders for fiscal year 2028. Information on the vote relating to the director standing for election is set forth below: Nominee For Withheld Broker Non-Votes Mr. Frederick W. Driscoll 2,360,948 842,254 1,096,736 Dr. Nicholas R. Glover 2,722,093 481,109 1,096,736 Proposal 2. – Advisory Vote on Executive Compensation. Proposal 2 was to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement. The proposal was approved. For Against Abstain Broker Non-Votes 2,127,143 456,162 619,897 1,096,736 Proposal 3. – Ratification of Appointment of Deloitte & Touche LLP. Proposal 4 was to ratify the appointment of Deloitte & Touche LLP, an independent registered public accounting firm, as the Company's independent auditors for the fiscal year ending June 30, 2025. The proposal was approved. For Against Abstain 4,255,692 33,846 10,400

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MEI PHARMA, INC. Date: January 31, 2025 By: /s/ Justin J. File Justin J. File Acting Chief Executive Officer, Chief Financial Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR